Baxter, bioMérieux NEPHROCLEAR CCL14 AKI Test Gains EU Nod

Baxter and bioMérieux earned CE marking of the NEPHROCLEAR CCL14 Test. The NEPHROCLEAR CCL14 Test is designed to predict persistent severe acute kidney injury (PS-AKI) and can be used to support timely clinical decision-making and care pathways. The companies intend to commercially launch the NEPHROCLEAR CCL14 Test in western Europe in 2022.
 
“Baxter is proud to partner with bioMérieux to offer the NEPHROCLEAR CCL14 Test as an important new diagnostic option to support individualized AKI management that gives every patient the greatest opportunity for recovery,” said Reaz Rasul, general manager of Baxter’s Acute Therapies business. “We remain committed to advancing purposeful innovation across the care continuum to help reduce complexity and enable efficiencies in critical care, especially as hospitals continue to feel the impact of the COVID-19 pandemic.”
 
“This new step in our collaboration with Baxter further strengthens our innovative diagnostics solutions portfolio for the management of AKI,” said Pierre Boulud, COO, clinical operations, bioMérieux. “True to our public health mission, we bring to the medical community this high-medical-value immunoassay that has the potential to change the current strategy of care for patients suffering from AKI.”
 
AKI is a sudden decrease in kidney function over a period of hours to days, often as a result of illness, trauma or infection. The sudden loss of kidney function leads to the accumulation of toxins and fluid in the blood that, if left untreated, may lead to death. Baxter recently collaborated with bioMérieux and Premier Applied Sciences (PAS) to conduct a study assessing the economic and clinical impact of PS-AKI. Data from this study presented at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) showed that PS-AKI (stage 3 AKI lasting ≥ 3 days) is independently associated with a longer length of stay and higher costs during index hospitalization and 30-day follow-up compared to non-persistent AKI. Additional data from this study, presented at the European Society of Intensive Care Medicine (ESICM) LIVES congress, showed that PS-AKI is prevalent among hospitalized adults in the U.S. and is associated with a significantly higher risk of death during hospitalization, as well as readmissions, dialysis and death during 30-day follow-up, compared to patients without PS-AKI.
 
A consensus statement from the Acute Disease Quality Initiative Consensus Conference underscores the importance of new biomarkers like CCL14 (C–C motif chemokine ligand 14), the biomarker measured by the NEPHROCLEAR CCL14 Test, in helping to manage AKI by identifying high-risk patient groups, guiding therapy and improving care pathways.¹ Recent studies published in Intensive Care Medicine,² Critical Care³ and Journal of Thoracic and Cardiovascular Surgery⁴ suggest that CCL14 is the most predictive biomarker of PS-AKI when compared with other AKI biomarkers, including NGAL, CHI3L1, L-FABP, Cystatin C, Proenkephalin, and KIM-1.
 
The NEPHROCLEAR CCL14 Test provides a reliable and precise measurement to help clinicians assess an individual patient’s risk for developing PS-AKI. The test’s area under the receiver operating characteristic curve (AUC), which is an indicator of the overall accuracy of a diagnostic test, is 0.82, illustrating the CCL14 biomarker’s ability to distinguish patients who will likely develop PS-AKI from those who will not.^2,5 The test results can help clinicians determine personalized treatment approaches for each patient, including level of care and the need for appropriate interventions, based on KDIGO (Kidney Disease Improving Global Outcomes) clinical practice guidelines.^3,5,6 When test results show a patient is at increased risk for PS-AKI, they may be triaged to a higher level of care to help mitigate potential complications of AKI.^2,3
 
Baxter and bioMérieux previously announced an agreement to develop and distribute this novel AKI biomarker test to assess the risk of PS-AKI and support clinical decision-making in AKI management. Both companies will provide support at the customer site for the NEPHROCLEAR CCL14 Test, while bioMérieux retains control over the regulatory approval process and Baxter retains control over the commercialization strategy. Baxter is bioMérieux’s exclusive distributor of the NEPHROCLEAR CCL14 Test in Europe and will also be the exclusive distributor in the U.S. pending clearance from the U.S. Food and Drug Administration (FDA).
 
References
¹ Ostermann M, Zarbock A, Goldstein S, et al. Recommendations on Acute Kidney Injury Biomarkers From the Acute Disease Quality Initiative Consensus Conference: A Consensus Statement. JAMA Netw Open. 2020;3(10):e2019209. doi:10.1001/jamanetworkopen.2020.19209
² Hoste E, Bihorac A, Al-Khafaji, A, et al. Identification and validation of biomarkers of persistent acute kidney injury: the RUBY study. Intensive Care Med 46, 943–953 (2020). https://doi.org/10.1007/s00134-019-05919-0
³ Bagshaw, S.M., Al-Khafaji, A., Artigas, A. et al. External validation of urinary C–C motif chemokine ligand 14 (CCL14) for prediction of persistent acute kidney injury. Crit Care 25, 185 (2021). https://doi.org/10.1186/s13054-021-03618-1
⁴ Massoth C, et al. Comparison of C-C motif chemokine ligand 14 with other biomarkers for adverse kidney events after cardiac surgery. J Thorac Cardiovasc Surg. 2021 Mar 10:S0022-5223(21)00436-0. doi: 10.1016/j.jtcvs.2021.03.016
⁵ BioMerieux NephroClear CCL14 Test Kit Package Insert
⁶ International Society of Nephrology. (2012) KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int. Suppl.2, 1-138. https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf